What is Alpha Cognition Inc. (ACOGF) stock price today?

Alpha Cognition Inc. (ACOGF) is currently trading at $5.73.

What is ACOGF P/E ratio?

Alpha Cognition Inc.'s P/E ratio is -38.17. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ACOGF return on equity (ROE)?

Alpha Cognition Inc.'s return on equity (ROE) is 456.59%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Alpha Cognition Inc.'s market cap?

Alpha Cognition Inc. has a market capitalization of $35.66M.

OTC · Biotechnology

Alpha Cognition Inc. (ACOGF) Stock

$5.73 OTC: ACOGF Healthcare

Valuation

Metric	Value
Price	$5.73
Market Cap	$35.66M
P/E Ratio	-38.17
P/B Ratio	-114.63
P/S Ratio	0.00
EPS (TTM)	$-0.15
52-Week High	$5.73
52-Week Low	$5.73
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	456.59%
ROA	-561.65%
ROCE	1000.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.26
Current Ratio	0.73

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-5.0M	$-6.0M	$-12.0M	$-13.0M	$-10.0M
Net Profit	$-7.0M	$-6.0M	$-20.0M	$-12.0M	$-14.0M
EPS	$-0.21	$-0.96	$-0.37	$-0.18	$-0.15
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$6.0M	$8.0M	$13.0M	$3.0M	$2.0M
Total Liabilities	$1.0M	$8.0M	$4.0M	$4.0M	$7.0M
Cash	$5.0M	$6.0M	$11.0M	$2.0M	$1.0M
Borrowings	$1.0M	$3.0M	$1.0M	$1.0M	$1.0M

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-3.0M	$-5.0M	$-10.0M	$-9.0M	$-9.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$6.0M	$2.0M	$1.0M	$0	$-1.0M
Net Cash Flow	$5.0M	$0	$5.0M	$-9.0M	$-1.0M
Free Cash Flow	$-3.0M	$-5.0M	$-10.0M	$-9.0M	$-9.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.19
EV / EBITDA	-3.66
FCF Yield	-24.48%
Quick Ratio	0.73
Interest Coverage	-140.76
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
DMTTFSmall Pharma Inc.	$0.11	-9.69%	-2.20	$37.51M	0.00%
ENZBEnzo Biochem, Inc.	$0.70	-0.16%	-8.80	$36.59M	0.00%
IGXTIntelGenx Technologies Corp.	$0.17	+0.00%	-2.99	$29.69M	0.00%
IMMPFImmuPharma plc	$0.09	+0.00%	-10.81	$28.34M	0.00%
KMSTFKadimastem Ltd	$3.21	-3.02%	-1.52	$9.50M	0.00%

About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for severe neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its developmental pipeline features ALPHA-1062, an acetylcholine esterase inhibitor designed to address dementia of the Alzheimer's type and mild traumatic brain injury. The company is also advancing ALPHA-0602, a gene therapy candidate specifically for ALS. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before officially changing its name to Alpha Cognition Inc. in March 2021. The corporate headquarters are located in Vancouver, Canada.

Alpha Cognition Inc. is headquartered in CA.

Alpha Cognition Inc. (ACOGF) stock trades at $5.73 with a market capitalization of $35.66M. The stock is valued at a price-to-earnings (P/E) ratio of -38.17, price-to-book of -114.63, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.73 and $5.73, and currently trades at its 52-week high.

On profitability, Alpha Cognition Inc. generates a return on equity (ROE) of 456.59% — well above the market average, a sign of a high-quality business, return on capital employed of 1000.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.alphacognition.com